Annals of Hematology

, Volume 96, Issue 5, pp 711–718 | Cite as

Clinical impact of galectin-3 in newly diagnosed t (15;17)(q22;q21)/PML-RARa acute promyelocytic leukemia treated with all-trans retinoic acid and arsenic trioxide-based regimens

  • Na GaoEmail author
  • Xue-Xia Wang
  • Jian-Rong Sun
  • Wen-Zheng Yu
  • Xi-Zhi Li
Original Article


Increased galectin-3 expression has been currently showed to be associated with poor prognosis in some hematological malignancies, such as acute myeloid leukemia, diffuse large B cell lymphoma. However, little is known about the clinical significance of galectin-3 in patients with acute promyelocytic leukemia (APL). We investigated the concentration of serum galectin-3 and characterized the relationship between galectin-3 and outcome in patients with APL. Higher galectin-3 levels were detected in patients with APL compared with the healthy controls (p < 0.001). Higher galectin-3 levels were closely associated with older ages (p < 0.001), the medical history of psoriasis (p = 0.036), coagulopathy (p = 0.042), and CD34 expression (p = 0.004). Compared with patients with lower galectin-3 levels, those with higher galectin-3 levels had significant shorter overall survival (p = 0.028) and relapse-free survival (p = 0.001). Multivariate analysis showed that serum galectin-3 was an independent unfavorable factor for relapse-free survival in patients with APL treated with all-trans retinoic acid and arsenic trioxide-based frontline therapy. Clinical impact of galectin-3 should be further investigated in patients with APL.


Acute promyelocytic leukemia Galectin-3 Prognosis Relapse Overall survival 



This work was supported by the Medical and Health science and Technology Development Program (2015WS0508) of Shandong and Binzhou Medical University Scientific Research Fund (BY2013KJ38).

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Supplementary material

277_2017_2948_MOESM1_ESM.docx (35 kb)
Figure S1 (DOCX 34 kb)
277_2017_2948_MOESM2_ESM.docx (36 kb)
Figure S2 (DOCX 35 kb)
277_2017_2948_MOESM3_ESM.docx (34 kb)
Figure S3 (DOCX 33 kb)


  1. 1.
    Breccia M, De Propris MS, Stefanizzi et al (2014) Negative prognostic value of CD34 antigen also in expressed on a small population of acute promyelocytic leukemia cells. Ann Hematol 93:1819–1823CrossRefPubMedGoogle Scholar
  2. 2.
    Montesinos P, Rayon C, Vellenga E et al (2011) Clinical significance of CD56 expression in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based regimens. Blood 117:1799–1805CrossRefPubMedGoogle Scholar
  3. 3.
    Xu F, Yin CX, Wang CL et al (2014) Immunophenotypes and immune markers associated with acute promyelocytic leukemia prognosis. Dis Mark 2014:421906Google Scholar
  4. 4.
    Lucena-Araujo AR, Kim HT, Jacomo RH et al (2014) Internal tandem duplication of the FLT3 gene confers poor overall survival in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based chemotherapy: an International Consortium on Acute Promyelocytic Leukemia study. Ann Hematol 93:2001–2010CrossRefPubMedGoogle Scholar
  5. 5.
    Jia W, Kidoya H, Yamakawa D et al (2013) Galectin-3 accelerates M2 macrophage infiltration and angiogenesis in tumors. Am J Pathol 182:1821–1831CrossRefPubMedGoogle Scholar
  6. 6.
    Jiang SS, Weng DS, Wang QJ et al (2014) Galectin-3 is associated with a poor prognosis in primary hepatocellular carcinoma. J Transl Med 12:273CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    de Oliveira JT, Ribeiro C, Barros R et al (2015) Hypoxia up-regulates galectin-3 in mammary tumor progression and metastasis. PLoS One 10:e0134458CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Braeuer RR, Zigler M, Kamiya T et al (2012) Galectin-3 contributes to melanoma growth and metastasis via regulation of NFAT1 and autotaxin. Cancer Res 72:5757–5766CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Kim SJ, Shin JY, Lee KD et al (2011) Galectin-3 facilitates cell motility in gastric cancer by up-regulating protease-activated receptor-1 (PAR-1) and matrix metalloproteinase-1 (MMP-1). PLoS One 6:e25103CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Yamaki S, Fujii T, Yajima R et al (2013) Clinicopathological significance of decreased galectin-3 expression and the long-term prognosis in patients with breast cancer. Surg Today 43:901–905CrossRefPubMedGoogle Scholar
  11. 11.
    Li ZW, Wang Y, Xue WC et al (2013) Expression and prognostic significance of galectin-1 and galectin-3 in benign nevi and melanomas. Zhonghua Bing Li Xue Za Zhi 42:801–805PubMedGoogle Scholar
  12. 12.
    Leal MF, Calcagno DQ, Chung J et al (2015) Deregulated expression of annexin-A2 and galectin-3 is associated with metastasis in gastric cancer patients. Clin Exp Med 15:415–420CrossRefPubMedGoogle Scholar
  13. 13.
    Hsu DK, Yang DY, Pan Z et al (2000) Targeted disruption of the galectin-3 gene results in attenuated peritoneal inflammatory responses. Am J Pathol 156:1073–1083CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Zhang R, Sun T, Song L, Zuo D, Xiao W (2014) Increased levels of serum galectin-3 in patients with primary Sjögren's syndrome: associated with interstitial lung disease. Cytokine 69:289–293CrossRefPubMedGoogle Scholar
  15. 15.
    Yamamoto-Sugitani M, Kuroda J, Ashihara E et al (2011) Galectin-3 (gal-3) induced by leukemia microenvironment promotes drug resistance and bone marrow lodgment in chronic myelogenous leukemia. Proc Natl Acad Sci U S A 108:17468–17473CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Hoyer KK, Pang M, Gui D et al (2004) An anti-apoptotic role for galectin-3 in diffuse large B-cell lymphomas. Am J Pathol 164:893–902CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Clark MC et al (2012) Galectin-3 binds to CD45 on diffuse large B-cell lymphoma cells to regulate susceptibility to cell death. Blood 120:4635–4644. doi: 10.1182/blood-2012-06-438234 CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Clark MC, Pang M, Hsu DK et al (2008) Increased serum 90 K and galectin-3 expression are associated with advanced stage and a worse prognosis indiffuse large B-cell lymphomas. Acta Haematol 120:211–216Google Scholar
  19. 19.
    Cheng CL, Hou HA, Lee MC et al (2013) Higher bone marrow LGALS3 expression is an independent unfavorable prognostic factor for overall survival in patients with acute myeloid leukemia. Blood 121:3172–3180CrossRefPubMedGoogle Scholar
  20. 20.
    van Dongen JJM, Macintyre EA, Gabert JA et al (1999) Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Leukemia 13:1901–1928CrossRefPubMedGoogle Scholar
  21. 21.
    Gabert J, Beillard E, van der Velden VHJ et al (2003) Standardization and quality control studies of real-time quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia: a Europe against cancer program. Leukemia 17:2318–2357CrossRefPubMedGoogle Scholar
  22. 22.
    Asgarian-Omran H, Forghani P, Hojjat-Farsangi M, Roohi A, Sharifian RA, Razavi SM et al (2010) Expression profile of galectin-1 and galectin-3 molecules in different subtypes of chronic lymphocytic leukemia. Cancer Investig 28:717–725CrossRefGoogle Scholar
  23. 23.
    D'Haene N, Catteau X, Maris C, Martin B, Salmon I, Decaestecker C (2008) Endothelial hyperplasia and endothelial galectin-3 expression are prognostic factors in primarycentral nervous system lymphomas. Br J Haematol 140:402–410CrossRefPubMedGoogle Scholar
  24. 24.
    Hu K, Gu Y, Lou L et al (2015) Galectin-3 mediates bone marrow microenvironment-induced drug resistance in acute leukemia cells via Wnt/β-catenin signaling pathway. J Hematol Oncol 8:1CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Sanz MA, Lo Coco F, Martín G et al (2000) Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA cooperative groups. Blood 96:1247–1253PubMedGoogle Scholar
  26. 26.
    Lehmann S, Ravn A, Carlsson L et al (2011) Continuing high early death rate in acute promyelocytic leukemia: a population-based report from the Swedish adult acute leukemia registry. Leukemia 25:1128–1134CrossRefPubMedGoogle Scholar
  27. 27.
    Avvisati G, Lo-Coco F, Paoloni FP et al (2011) AIDA 0493 protocol for newly diagnosed acute promyelocytic leukemia: very long-term results and role of maintenance. Blood 117:4716–4725CrossRefPubMedGoogle Scholar
  28. 28.
    Chendamarai E, Ganesan S, Alex AA et al (2015) Comparison of newly diagnosed and relapsed patients with acute promyelocytic leukemia treated with arsenic trioxide: insight into mechanisms of resistance. PLoS One 10:e0121912CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Iland HJ, Bradstock K, Supple SG et al (2012) All-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4). Blood 120:1570–1580CrossRefPubMedGoogle Scholar
  30. 30.
    de Thé H, Chen Z (2010) Acute promyelocytic leukaemia: novel insights into the mechanisms of cure. Nat Rev Cancer 10:775–783CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2017

Authors and Affiliations

  • Na Gao
    • 1
    Email author
  • Xue-Xia Wang
    • 1
  • Jian-Rong Sun
    • 1
  • Wen-Zheng Yu
    • 1
  • Xi-Zhi Li
    • 2
  1. 1.Department of hematologyBinzhou Medical University HospitalBinzhouChina
  2. 2.Department of nephrologyBinzhou Medical University HospitalBinzhouChina

Personalised recommendations